115 results
8-K
EX-99.2
AXDX
Accelerate Diagnostics Inc
6 Nov 20
Accelerate Diagnostics Reports Third Quarter 2020 Financial Results
4:19pm
by our commercial team during the quarter.
Limited hospital access and competing pandemic-related priorities in the microbiology lab continued to impact … acuity samples like isolates in urine. Key hardware advances were made during the quarter which enables simultaneous and random access testing
8-K
EX-99.2
AXDX
Accelerate Diagnostics Inc
12 Nov 21
Accelerate Diagnostics Reports Second Quarter 2021 Financial Results
4:12pm
outlined that increasing the rate of adoption of our integrated ID/AST solution would require a normalization of hospital priorities and access … and to be further supported by positive readout from our registry study and the implementation of product improvements.
In the second quarter hospital access
8-K
EX-99.2
AXDX
Accelerate Diagnostics Inc
12 Nov 21
Accelerate Diagnostics Reports Third Quarter 2021 Financial Results
4:12pm
access and focus. This latest disruption was due to 2 factors: first, as Delta variant hospitalization surged in specific regions and cities, non-COVID … and placements were lower than anticipated. The resurgence of COVID delayed go lives, impacting near-term revenues and prevented access to customer
8-K
EX-99.1
AXDX
Accelerate Diagnostics Inc
13 Dec 23
December 2023 Company Presentation
5:05pm
with random access for critical samples Pheno® On-market Learnings Wave™ builds on Accelerate’s early innovation and technological leadership in the ID / AST … , and administrative relationships at ~500 accounts worldwide ✓ Securing a partnership with a multi-national partner provides potential access to a global
8-K
EX-99.2
AXDX
Accelerate Diagnostics Inc
13 Jan 21
Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
9:45am
customer base for aggressive share capture: Referral & regional strategy expansions Improving access to new opportunities Increasing focus on secondary … Enabling increased margin profile & access to higher volume samples Supporting random - access/high - throughput analysis of diverse samples Engineered
8-K
EX-99.2
ay6g2t yxjxe
6 Nov 20
Accelerate Diagnostics Reports Second Quarter 2020 Financial Results & Announces New Product Offering
11:59am
8-K
EX-99.1
t0xqr1lq
14 Dec 07
Other Events
12:00am
8-K
EX-99.1
47d11ym 198n
7 Jan 19
Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results
6:21am
8-K
EX-99.1
bumxh
26 Jan 01
Current report
12:00am
8-K
EX-99.1
1t8dhyad
13 Jan 21
Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
9:45am
8-K
EX-99.1
dqvgocaty7wxv1 ojeg
16 Apr 20
Results of Operations and Financial Condition
12:00am
8-K
EX-99.2
o72xhkk1 iity6h0ssng
15 Nov 22
Accelerate Diagnostics Reports Third Quarter 2022 Financial Results
4:49pm
S-1/A
EX-4.7
6r31ln4 px4v
16 Jan 24
IPO registration (amended)
7:18am
S-1/A
EX-4.6
8ewa0w1r2dmr7s 8mzg
16 Jan 24
IPO registration (amended)
7:18am
8-K
EX-10.1
lxadq011q3e 1ymw
21 Aug 19
Entry into a Material Definitive Agreement
3:00pm